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The COVID-19 pandemic seemingly is peaking now in New
York City and has triggered signiﬁcant changes to the
standard management of gastrointestinal diseases. Priorities such as minimizing viral transmission, preserving
personal protective equipment, and freeing hospital beds
have driven unconventional approaches to managing
gastroenterology (GI) patients. Conversion of endoscopy
units to COVID units and redeployment of GI fellows and
faculty has profoundly changed the proﬁle of most GI services. Meanwhile, consult and procedural volumes have
been reduced drastically. In this review, we share our collective experiences regarding how we have changed our
practice of medicine in response to the COVID surge.
Although we review our management of speciﬁc consults
and conditions, the overarching theme focuses primarily
on noninvasive measures and maximizing medical therapies. Endoscopic procedures have been reserved for those
timely interventions that are most likely to be therapeutic.
The role of multidisciplinary discussion, although always
important, now has become critical. The support of our
faculty and trainees remains essential. Local leadership
can encourage well-being by frequent team check-ins and
by fostering trainee development through remote learning.
Advancing a clear vision and a transparent process for how
to organize and triage care in the recovery phase will allow
for a smooth transition to our new normal.
Keywords: COVID-19; PPE; NYSGE; Guidelines; Consults;
Experience.

y April 10, 2020, the number of COVID-19 cases in
New York reached nearly 160,000 (with >92,000
cases in the metropolitan region alone), a staggering and
grim state statistic that alone exceeded that of any country. On March 16, 2020, approximately 1 week before
New York was labeled the epicenter of the pandemic,
the New York Society for Gastrointestinal Endoscopy issued guidelines that built on those from national societies and published narratives from other global

B

epicenters.1–4 The urgent communication strongly
emphasized prioritization of endoscopic procedures, outlined operational practices of the endoscopy suite, and
deﬁned personal protective equipment (PPE) standards
to be followed during endoscopy. However, our growing
experience and variability in regional rates of infections,
availability of resources, and institutional guidance necessitates tailoring of national recommendations. Most
guidelines have yet to address practical changes to management of gastroenterology (GI) consults and common
GI issues in response to the pandemic.
This review describes how GI consultative services
and management of some disease-speciﬁc illnesses such
as inﬂammatory bowel disease (IBD) have been redesigned throughout hospitals in the New York metropolitan area, not unlike how practicing (and in some cases
previously retired) gastroenterologists have been redeployed as COVID hospitalists and endoscopy suites have
been repurposed as COVID care units. These modiﬁcations follow several guiding principles that are listed in
Table 1 and focus on rethinking methods for the
assessment of patients with gastroenterology diseases,
modifying strategies for intervention, and working in
tandem with other services to achieve acceptable outcomes. An unexpected consequence of this virus’s attack
is the hijacking of our standards of excellence and
coercion to change our practice in ways that contradict
our sensibilities. This review describes some of our

Abbreviations used in this paper: ASC, ambulatory surgical center; EN,
enteral nutrition; ERCP, endoscopic retrograde cholangiography; EUS,
endoscopic ultrasound; GI, gastrointestinal; IBD, inﬂammatory bowel
disease; ICU, intensive care unit; NGT, nasogastric tube; OR, operating
room; PPE, personal protective equipment.
Most current article
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Table 1. Minimizing Endoscopy Utilization and Conserving
Resources
First consider noninvasive testing (ie, radiography)
Maximize medical therapies before procedural intervention
Consider interventional radiology, if resources allow
Prioritize procedures that reduce length of stay (percutaneous
endoscopic gastrostomies, but favor interventional radiology
G-tube over percutaneous endoscopic gastrostomy)
Encourage procedures that avoid surgery (ie, colonic stenting)

proposed solutions to these unfamiliar challenges. By
sharing our collective experiences we hope that regions
of the country that have yet to endure the full brunt of
this contagion will be better informed to implement
similar strategies and mitigate what has proven to be a
relentless and sustained attack on us all.

Repurposing of Endoscopy Units and
Gastrointestinal Services
Nothing about the practice of endoscopy was unscathed as the pandemic inundated the city. By the third
week of the pandemic, the large hospital systems were
40% to 80% ﬁlled with COVID patients, with up to 25%
requiring intensive care unit (ICU) care in some locations.
On average, GI services in these hospitals decreased their
procedural volume by 80% to 90%, and the consultative
volume by 50%. By the time of this writing, repurposing
endoscopy suites to COVID care units has occurred in
many of the hospital systems in the region. Procedures
now largely are relegated to the operating room (OR) or to
the bedside in ICUs, and approved indications remain
sharply restricted. Anesthesiologists and their equipment
are being used to furnish makeshift ICUs while endoscopy
staff, including GI faculty and many of New York’s 400
fellows, are redeployed throughout the hospital. Many
institutions have created central OR committees to review
all procedures and surgeries to ensure fair provision of
resources across the hospital. GI procedures and consults
are performed by only 1 to 2 faculty members, most often
a general GI consult attending and an interventionist, who
is not typically in the hospitalist redeployment pool.
Undeployed fellows play supporting and non–patientcontact roles or staff virtual outpatient consults. Finally,
some programs have consolidated all GI services,
including subspecialty services such as pancreaticobiliary,
IBD, and transplant hepatology into one consultative
service for all consults.
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indications of procedures, use of PPE, and endoscopy suite
etiquette. However, over the few weeks that followed individual institutions went through volatile changes of PPE
availability that mandated revised policies. By executive
order, ambulatory surgical centers (ASCs) were mandated
to stop performing elective procedures and as a result
many have been forced to close entirely. Some centers,
particularly those with hospital afﬁliations, have been
repurposed as COVID care centers while others have
redirected staff and equipment resources to assist in the
COVID response. Sustained community transmission combined with still limited availability of testing, high falsenegative rates (w40%), and a presumed high prevalence
of asymptomatic carriers has forced revision of guidelines,
including those listed in Table 2, to be followed for procedures regardless of venue or a patient’s COVID status.
Changes in indications for procedures are discussed separately later. Because most procedures now occur offsite,
efforts should be made to perform them during the day
when more resources and staff are available to manage
intraprocedural modiﬁcations or complications.

Gastrointestinal Bleeding
Although some specialties have reported a decrease in
their most common emergencies, such as heart attacks,5
signiﬁcant gastrointestinal (GI) bleeding remains prevalent and this includes complications from COVID-related
illness (Mallory–Weiss tears, profound diarrhea, and
hypovolemic-induced ischemic colitis). A recent regional
survey showed that 70% of consults during this time are
for GI bleeding.6 Although overt GI bleeding typically
prompts a rapid endoscopic evaluation, procedural parsimony is the new rule. Across institutions, our consensus
found that urgent upper endoscopies rarely were performed within the ﬁrst 24 hours. Similarly, procedures for
lower GI bleeding nearly uniformly were deferred and have
been postponed to the outpatient venue. Although these
strategies were not driven by prepandemic studies
regarding the timing of endoscopic intervention, this practice fortuitously has been reﬂected in emerging literature.7,8
Returning to basic principles of resuscitation, optimizing medical management, and exhausting alternative
Table 2. Guidelines to Be Followed for All Endoscopic
Procedures

Updates on Guidelines for Indications,
Personal Protective Equipment, and
Procedural Logistics

Manage all patients as if COVID positive
Use negative-pressure rooms whenever possible (endoscopy, OR,
ICU)
Limit in-room staff to critical personnel only
All personnel to don full PPE, including N95 masks
Consider endotracheal intubation or procedural oxygen mask for all
upper endoscopies
Exclude trainees from procedures as much as possible

As indicated previously, early local guidelines followed
national and international recommendations regarding

ICU, intensive care unit; OR, operating room; PPE, personal protective
equipment.
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diagnostic modalities allows us to focus only on the
procedures that are most likely to be therapeutic. COVID19 infection can mimic or exacerbate the hemodynamic
effects of GI bleeding and an effort should be made to
discern between the two by administering acetaminophen, intravenous ﬂuid, and blood products as indicated.
Although aggressive medical management should be
individualized, it is worth considering proton pump inhibitor infusions over intermittent intravenous administration; liberalized octreotide infusions for patients with
suspected or known liver disease; scheduled antiemetics,
platelets, and/or clotting factors to correct iatrogenic or
acquired coagulopathies; and reversal agents if appropriate. Emerging experience in critically ill COVID patients suggests that they can develop a prothrombotic
form of disseminated intravascular coagulation, placing
them at a dramatically increased risk of thrombosis.
Many of these patients therefore may be receiving newly
prescribed anticoagulants that need to be considered
when evaluating and managing GI bleeding issues in this
cohort.
In hemodynamically stable cases in which active upper GI bleeding is in the differential but remains indeterminate, we propose pursuing alternative diagnostic
modalities such as computed tomography angiography
and bedside real-time viewer capsule endoscopy. Nasogastric tube (NGT) lavage in ventilated patients, a
somewhat outdated maneuver, still should be considered
a useful test if blood return is shown. This is not advised,
however, in the unsedated patient because of the risk of
gagging, vomiting, and aerosolization.
Established parameters for assessments of acuity and
severity of GI bleeding remain unchanged. These include
the volume of visualized blood loss, blood loss based on
laboratory values (both absolute and relative to baseline), rate of blood loss, response to transfusion, and
hemodynamics. Physical examination of inpatients now
is discouraged unless the ﬁndings are expected to impart
acute changes in management. We have found that
photographic documentation of bleeding (emesis basin,
bedsheets, and toilet bowls) by the patient or staff has
been increasingly helpful in conﬁrming symptoms and
guiding remotely based decisions.
Inpatient GI consult services are deferring endoscopic evaluation in patients with anemia without
overt bleeding, with reported/observed small-volume
bleeding, self-limited bleeding, and, given the low
therapeutic potential, this includes almost all lower GI
bleeding. Once restrictions begin to lift and as the
word recovery begins to appear in our institutional
communications, these patients should be considered
among the ﬁrst group to receive endoscopic evaluation
while further prioritizing patients with ongoing symptoms or the need for anticoagulation and/or antiplatelet therapy.
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Dysphagia, Nausea, Vomiting, and
Diarrhea
Inpatients or outpatients with symptoms of
dysphagia should be assessed for their ability to tolerate
sufﬁcient oral intake to maintain proper weight and
nutrition. Patients with mild to moderate dysphagia may
need to defer evaluation and therapy. Data are lacking
for testing, such as esophageal manometry, but given the
prevalence of coughing during intranasal placement,
New York City centers have postponed testing. Noninvasive radiographic studies such as barium esophagram
may be useful to triage the need for endoscopy, however,
the local availability of radiology services and department policies will need to be considered as well. We have
found that very few patients have been sent for timed
contrast studies for any indication. Consensus indications for prompt endoscopy include an inability to
tolerate a sufﬁcient liquid diet with ongoing dehydration/profound weight loss or foreign body or food
impaction with an inability to tolerate secretions after
intravenous glucagon has failed.9 Options for nutritional
management of patients with dysphagia are discussed
later.
COVID-19 can present with nausea, vomiting, and
diarrhea, and these can predate respiratory symptoms.
In a recent report, up to 61% of outpatients who
tested positive for COVID-19 experienced these GI
symptoms.10 During the peak of the epidemic, acute
nausea, vomiting, or diarrhea should be considered
COVID-related until proven otherwise. Outpatients
should self-quarantine and minimize exposure to
household contacts. For all inpatients and ongoing
symptoms in outpatients, GI pathogen testing including
Clostridium difﬁcile should be considered, particularly
in patients with signs such as leukocytosis or those
with risk factors such as recent antibiotic use. In the
absence of a bacterial pathogen, medical management
with anti-emetics and antidiarrheals (eg, loperamide)
can be optimized. Careful monitoring of the QTc is
essential because many anti-emetics prolong the QT,
particularly when combined with other agents being
used for COVID-19 that also affect the QTc (hydroxychloroquine and azithromycin). Some institutions have
hospital-wide protocols in place to monitor the QTc
and reduce risk of Torsades de pointes.
Special circumstances may lower the threshold for
endoscopic evaluation for nausea, vomiting, or diarrhea. This includes evaluation for graft-versus-host
disease in bone marrow transplant patients and for
immune-mediated colitis in patients receiving checkpoint inhibitors. If an infectious work-up is unrevealing
and patients remain symptomatic after maximizing
medical therapy, patients should proceed to endoscopy
in efforts to avoid empiric immunosuppression.
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Enteral Nutrition and Access
Consults for gastrostomy placement have decreased
dramatically across institutions in New York, with fewer
than 1 to 2 referrals per week for percutaneous endoscopic gastrostomy as per a recent New York–based
survey.6 Although prolonged intubation typically warrants gastrostomy placement, it is possible that the high
associated mortality rate, and need to decrease invasive,
aerosolizing procedures in COVID-19–infected patients,
has resulted in infrequent gastrostomy placement.
The timing and method of gastrostomy placement
should be largely individualized to the services and resources available at a particular location. It is recommended to bring all of the procedural services that place
feeding tubes, along with ICU management, together to
establish a workﬂow. Within the New York City area,
most gastrostomies in patients testing positive for
COVID-19 are being placed by interventional radiology,
especially if the patient already has a NGT in place.
Finding the optimal timing for gastrostomy placement
in COVID-positive patients is critical and must weigh the
safety of staff with the associated potential for serious
adverse events, such as bleeding, infection, and death. We
propose a gastrostomy be considered once the patient has
shown clinical improvement and a probable chance of
discharge. This implies continuing enteral nutrition (EN)
with an NGT until discharge seems likely. For patients
requiring ICU level of care, the patient should be afebrile, in
no need of pressor support, with stable hemodynamics, and
all potentially complicating conditions (ie, disseminated
intravascular coagulation, paralytic ileus, and so forth) be
optimized before gastrostomy placement. Although we
recognize that nutrition is important for recovery, rushing
into invasive procedures can potentially hinder recuperation. Parenteral nutrition is not recommended for patients
with COVID infection owing to the risk of infection and/or
thrombosis.
Bedside percutaneous endoscopic gastrostomy placement in the ICU is the preferred venue if the room is
outﬁtted with negative pressure. However, most patients
will have a previously placed NGT (which may impede
discharge) and an interventional radiology–placed gastrostomy may be preferred for such patients who are not
intubated but continue to have respiratory symptoms and
high oxygen requirements. Consideration should be given
to the increasingly described hypercoagulable state seen in
critically ill COVID patients. In patients who ﬁt the criteria
for anticoagulation, we recommend continuing to follow
guidelines such as those outlined by the American Society
for Gastrointestinal Endoscopy in 2016.11

Enteral Nutrition via Weighted Nasogastric
Tube in the Prone Position
Many intubated patients with pulmonary disease
consistent with acute respiratory distress syndrome
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from COVID are being placed in the prone position.
Feeding in the prone position may lead to decreased
gastric emptying, vomiting, and aspiration, but studies
have shown mixed results. van der Voort et al12
showed that EN can be continued when a patient is
turned from supine to prone position (or vice versa)
without consequence. The results indicated that patients with a clinically signiﬁcant gastric residual volume in one position still are likely to have a clinically
signiﬁcant gastric residual volume in the other position. Reignier et al13 later concluded that early EN is
poorly tolerated in the prone position and use of a
prokinetic agent should be considered. Subsequent
meta-analyses have not suggested a substantial increase in complications when EN is administered in
the prone compared with the supine position.14 We
suggest that EN via NGT while prone should be used
with caution and patients should be watched for signs
of intolerance or vomiting.

Interventional Endoscopy
Management of interventional services leading up to
the peak of the crisis has been particularly challenging
owing to the restrictions in allocated endoscopy space
and resources in rooms not properly outﬁtted for interventional procedures. Within days, indications for interventional procedures dwindled down to those that
needed to be performed within 48 hours to prevent
admission, would enable discharge, or, less uniformly,
enable neoadjuvant chemotherapy (Tables 315 and 4). On
average, the interventional procedures saw a reduction
of 30% to 40%, the majority of which were endoscopic
retrograde cholangiography (ERCP). Throughout the region’s institutions, interventional procedures are
reviewed by either central committees or evaluated
(remotely) by 2 members of the advanced endoscopy
team to conﬁrm appropriateness and obtain all endoscopy unit approvals (nursing, anesthesia, scheduling)
before proceeding.
The most common indications for emergent interventional procedures have been cholangitis and
obstructive jaundice. Although emergent ERCP remains
Table 3. Procedures Considered Indicated During the
Pandemic
ERCP for cholangitis15
ERCP for gallstone pancreatitis
ERCP for symptomatic pancreatic or biliary disease
EGD/ERCP/EUS for palliation of luminal and pancreaticobiliary
obstruction
EUS for infected, symptomatic/obstructing ﬂuid collections 
necrosectomy
Any endoscopic procedure that will urgently change management

EGD, esophagogastroduodenoscopy; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound.
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Table 4. Procedures Considered Suitable for Delay and
Re-evaluation
ERCP for incidentally found/asymptomatic choledocholithiasis
ERCP for elective pancreatic or biliary stent change
ERCP for evaluation of nonobstructing pancreatic or biliary stricture
EUS for pancreatic cyst
EUS for subepithelial nonobstructing mass
EMR/ESD of benign lesions or superﬁcial malignant cancers
ERCP/EUS for evaluation/surveillance/treatment of premalignant or
malignant conditions, staging malignancy before chemotherapy
or surgery
EGD for elective therapy of varices
EUS for asymptomatic ﬂuid collections
EGD for upper GI tract stent exchange
ERCP for incidentally found or syndromic-related ampullary adenoma
All endobariatric procedures
Ablative techniques for LGD/HGD Barrett’s esophagus

EGD, esophagogastroduodenoscopy; EMR, endoscopic mucosal resection;
ERCP, endoscopic retrograde cholangiopancreatography; ESD, endoscopic
submucosal dissection; EUS, endoscopic ultrasound; GI, gastrointestinal;
HGD, high-grade dysplasia; LGD, low-grade dysplasia.

the treatment of choice, a lower threshold for percutaneous transhepatic cholangiography should be instituted
for
hemodynamically
unstable
patients,
particularly if mobilization is difﬁcult, such as in ICUs,
or when endoscopy is performed in shared space and
timely intervention cannot be performed. For patients
with presumed malignant biliary obstruction, the decision to obtain both a tissue diagnosis via endoscopic
ultrasound (EUS) with ﬁne-needle aspiration and
biliary
decompression
with
ERCP
is
fairly
straightforward.
There are no data deﬁning the urgency of chemoradiotherapy for GI cancers and most centers have a
short-term (ie, 4 weeks) deferral plan. However, if
local resources are robust and curative cancer surgery
similarly is deferred or is otherwise not appropriate,
select cases have undergone tissue acquisition with
EUS ﬁne-needle aspiration or ERCP with the intent of
initiating systemic therapy. However, if there is no
immediate plan for medical oncologic treatment or if
the patient is COVID positive and cannot yet begin
such therapy, the decision to defer tissue acquisition is
reasonable. It is especially important now to recall that
interventional procedures should not occur in a silo,
and decision making should be vetted through a
multidisciplinary process or be presented at a virtual
GI tumor board. Finally, some consideration should be
given to therapeutic maneuvers performed or types of
stents such that there is minimal risk of delayed
complications and the subsequent need for reintervention in the near future.
Despite the reasonable assumption that alcohol
intake has increased during the pandemic, far fewer
patients have been admitted with acute pancreatitis
during the COVID-19 crisis. Medical management of
patients with acute pancreatitis should be optimized
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with the goal of deferring otherwise indicated procedures, such as ERCP and sphincterotomy in gallstone pancreatitis or drainage of pancreatic ﬂuid
collections. Intervention should be reserved for
deteriorating clinical status and signs of impending
sepsis.
Malignancy-related bowel obstruction is common, is
not always amenable to surgical intervention, and can
delay chemotherapy. Venting gastrostomies should be
considered as urgent procedures for palliation of
small-bowel obstruction if a patient will not be
accepted to hospice with a nasogastric drainage tube.
In the setting of COVID-19 and restricted access by
surgeons to the OR, colonic and duodenal stenting for
large-bowel and gastric outlet obstruction, respectively,
should be prioritized as urgent procedures if in line
with the patient’s goals of care. Partial bowel obstructions should be managed medically for as long as
possible.
Complex interventional procedures such as EUSguided ERCP, third-space endoscopy, or tumor resection have been deferred at this time given the time
constraints of available shared anesthesia time,
increased risk associated with the procedures,
decreased access to resources for management of
complications such as surgical intervention, and need
for potential postprocedure admission and prolonged
hospital stay.
There are no guidelines for how to integrate radiation
protection (lead-equivalent attire with a thyroid shield)
into the required level of PPE. We recommend ﬁrst
donning the head and shoe covers before donning radiation protection, and then proceeding with the donning
sequence for the remainder of PPE. Radiation-protective
attire should be wiped down with disinfectant immediately after use.

Hepatology and Work-Up of Abnormal
Liver Tests
Considerations for hepatology-related consults, such
as increased liver function tests, complications of
cirrhosis, and variceal bleeding, are not discussed in this
review. Our consensus suggests most hepatology services defer to very recently published clinical insights
released by the American Association for the Study of
Liver Diseases.16 We recommend readers reference this
resource as well.

Inﬂammatory Bowel Disease
There are a myriad of logistical and clinical challenges
that have disrupted IBD care during the pandemic. We
present some of the most common scenarios
encountered.
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Fear of Exposure to COVID-19 When
Presenting for Hospital-Based Infusions and the
Concerns Associated With Using Public
Transportation
Practices with a hospital-based infusion center should
expect to receive a high volume of patient calls. Many
patients expressed a great fear of coming to a hot zone to
receive immunosuppressive therapies. In fact, we shared
their concerns and worked with hospital administration
to move the infusion center to a sister location that does
not receive COVID-19 patients, allaying many fears on
the part of the patients and the treating physicians.
By using published guidance from the national
gastroenterology societies, we were able to reassure
patients of the suggested beneﬁt of continuing maintenance therapy and that staying in remission outweighed
the risks of therapy discontinuation. Although most
centers might reload the medication for the inevitable
cases of delayed and deferred treatments, strong
consideration should be given to avoiding repeat loading
doses during the peak pandemic period. Unless there is a
suggestion of ﬂare symptoms, we prioritized obtaining
and/or maintaining symptomatic control over achieving
therapeutic target drug levels.
Expert consensus supports ongoing use of infusion
centers, provided a COVID-19 screening protocol is in
place.17,18 Although electively switching to injectable
therapies may seem attractive, and in some cases is the
only option, this strategy has been shown previously to
be associated with relapses.19 It is appropriate to
acknowledge both the patients’ fears and the dearth of
clear data on the outcomes of COVID-19 infection among
a biologic-treated population. By using a shared decisionmaking model one can negotiate how long a patient may
safely delay infusions.

Establishing Access to Therapies and Choosing
Alternative Therapies
Some immunosuppressed patients have ﬂed New
York City because it is currently the epicenter of the
pandemic. This creates challenges coordinating infusions
because many ofﬁces are not seeing new patients, or
have limited appointments, creating a long wait time for
patients to see a new provider. Some patients cannot
get alternative access to treatments and require remote
care. Although potentially suboptimal, this may require
switching to subcutaneously administered in-class therapies. In cases in which this option does not yet exist
(anti-integrin therapy), consider delaying infusions or
advocating with local physicians to transfer care seamlessly. Home infusions for patients in other states creates
new logistical challenges. Unless the patient has established a relationship with a local physician who would be
able to manage any complications, we are reluctant to
support this strategy. Furthermore, home infusions may
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introduce a risk that a nurse provider traveling between
multiple sites could become a virus vector.
This also gives rise to the question of whether smallmolecule therapy may be considered a preferred option
for moderate to severe ulcerative colitis among patients
seeking an alternative to injection/infusion biological
therapy. Current consensus opinion avoids initiating
treatment with tofacitinib during the pandemic.20 There is
concern that tofacitinib might inhibit viral immunity in
light of a clear association with the reactivation of herpes
zoster virus.18 Furthermore, despite a short half-life,
studies in the general population found defects in immune function up to 1 month after the drug was stopped.18
Initiation of biologics is controversial across the
various guidelines. Unlike Renmin Hospital in Wuhan,
China, which decided to stop all biologics for their IBD
patients,21 the United States and European guidelines
recommend
continuing
IBD
medication
regimens.18,20,22–24 In the International Organization for the
Study of Inﬂammatory Bowel Diseases guidelines, a patient with a new diagnosis or relapsing disease is recommended to be treated similar to pre–COVID-19 era,
although this was not a high consensus recommendation.18 We agree that delaying initiation of biologics in
patients who have manageable symptoms is a preferred
strategy. Although some published guidelines recommend avoiding initiation of steroids or monotherapy
with biologics during the pandemic,20 this must be
weighed against the need to avoid an emergency room
evaluation and hospitalization, locations that have
become synonymous with the presence of COVID-19.
It will be increasingly important in IBD care to
continually reassess whether patients treated with biologics have worse outcomes with concomitant COVID19 infection. The Surveillance Epidemiology of Coronavirus Under Research Exclusion-IBD registry25 may be
best positioned to determine that in real time.

Immunosuppressed Patients Who Work in
Health Care Settings
Available guidelines do not resolve whether health
care workers with known COVID-19 exposure on
immune-modifying medications should continue working. Given the possibility that immunocompromised patients will develop more severe COVID-19 illness, we are
advising immunosuppressed health care workers to
avoid COVID-19 patient interactions. Ustekinumab is
considered to have less biological effect on viral immunity than anti–tumor necrosis factor in the COVID-19
guidelines.17,18 However, in the absence of real-world
data on outcomes of COVID infection among immunocompromised IBD patients, we have provided uniform
recommendations to those on maintenance immunomodulators, anti–tumor necrosis factor therapies, antiintegrin
therapies,
anti-12-23
therapies,
and
prednisone-equivalent doses greater than 20 mg/d, to
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avoid the hospital setting and avoid patient-facing duties.
This simpliﬁed decision making also allowed a uniform
response from fellows and nurse practitioners who are
often the front line in managing the large volume of calls
generated.

Is the Decision to Delay Surgery Always the
Right One?
The decision to pursue surgery in patients with IBD
already is consensus driven. However, during this
pandemic, as discussed earlier regarding interventional
procedures, there is a preference to delay surgeries and
to try to stabilize patients with maximal medical management. For example, although not our standard practice, we have been able to manage perianal abscesses
with temporizing measures including antibiotics and
drainage by our surgical colleagues in the ofﬁce setting
rather than sending them for surgery. Conversely, complications for which we might ordinarily use conservative management such as total parenteral nutrition and
antibiotics for Crohn’s-related microperforation, have
warranted more urgent surgical intervention because of
uncertainty regarding access to medications, home care,
and the time course for deferred surgeries.26

Emotional and Leadership Aspects of
the Pandemic
All of the large academic medical centers in the New
York City region have deployed surge teams to meet the
demands of the massive inﬂux of COVID-19 patients.
Teams consist of attending physicians, fellows, residents,
and other providers from a variety of specialties, ranging
from internal medicine to dermatology. Many physicians,
including gastroenterologists, express reluctance to take
on these new responsibilities given their often long hiatus from internal medicine training. The main areas of
care of COVID patients are following institutional protocols for medical management, helping to maintain close
communication with patients and families, and navigating a complex and possibly entirely foreign inpatient
electronic health record.
Successful strategies to care for these patients include
ensuring there is one physician on each team (usually a
resident or advanced care provider) who is adept with
the inpatient electronic health record. Anxiety regarding
the medical care of COVID patients usually is alleviated
after onboarding, including reviewing protocols for PPE
and those for disease management.
The emotional burden of the COVID-19 pandemic has
been extraordinary, not only for patients, but also for
physicians (including those who have not been deployed
to the front lines) and training programs. Work–life
balance takes on new meaning and challenges because
physicians have to ﬁnd ways of crafting telehealth
practices and virtual meetings, while creating in-home
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classrooms, and continue to deal with daily household
needs. Similar to our colleagues everywhere, reconciling
our commitment to colleagues and patients with our
obligation also to protect our families can be distressing.
Successful coping strategies include acknowledgment of
the true pandemic degree of the challenges that now
exist, that one is not alone in managing this collateral
damage, and practicing a learned optimism.27 A renewed
focus on communication within families, as well as
ensuring proper time for self-care (including many
now complementary mindfulness applications such as
HeadSpace, Santa Monica, CA), is central to success.
Because telehealth and physical distancing have
compounded the isolation, frequent division check-ups
through teleconferences and telephone calls to trainees
is critical. To prevent feelings of isolation, it is paramount
to initiate early, sustained messaging that encourages
trainees to feel safe sharing emotional and health concerns with faculty members. Early changes in fellows’
educational curriculum include conversion to weekly
teleconferences and webinars. To help foster a sense of
regional community and honor the education goals of
our society, the New York Society for Gastrointestinal
Endoscopy quickly created a lecture series for fellows
and members as well as informational webinars to assist
with deployment to medicine. This connectivity helped
boost morale and remind us that we as a community can
weather these challenging times together.
It is not surprising that ethical and end-of-life
considerations have featured prominently in the management of patients during this pandemic. Although we
as gastroenterologists may not historically have been
the primary teams leading goals-of-care discussions for
consulted patients, the difﬁcult decisions need to be
addressed by all care team members. We suggest
seeking early (likely virtual) palliative care team input,
as well as becoming familiar with institutional policies
that surround rationing of care. There are welldeveloped online resources, including sample scripts
and video tutorials, to help get goals-of-care conversations started.28

Navigating the Road to Recovery
As inpatient procedures are deferred and new consults are managed with minimized assessments, a dedicated effort should be made to follow up these patients
closely as outpatients and to complete thorough assessment and treatment as the surge retreats and resources
are freed. Strategies include establishing dedicated
outpatient clinics (both fellow and faculty, virtual and inperson) for patients seen as consults, fellow maintenance
of consult registries to ensure close follow-up evaluation,
and using a scoring or tiered classiﬁcation system to help
prioritize which patients should be brought back for reassessment or for procedures, and in what time frame
(2–3 weeks, 1–3 months, or 6 months).
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In addition, hospital systems are considering using
their ASCs or partnering with external ASCs to begin to
address those patients discussed here, particularly
whose evaluation was deferred during hospitalization or
because of active infection. The role, availability, and
accuracy of Food and Drug Administration–approved
point-of-care testing will vary regionally and practices
should follow institutional or regional guidance
regarding the eligibility of patients to be treated. Ascertainment of convalescent antibodies may permit safe
development of care teams to be deployed in the highestrisk environments. Although we will need institutional
guidance regarding PPE during the recovery phase, we
should be reminded that, although not adopted by all,
universal precautions previously had been established as
the standard of care during endoscopies, and that we
should be returning to these principles as our new
baseline.29 The potential legal implications of minimized
and delayed care have yet to be deﬁned but will be
another area in which physicians will need to work
closely with local leadership to ensure establishment of
effective policies.

Conclusions
The COVID-19 pandemic arguably may be the most
difﬁcult challenge many of us will face in our professional careers. For New Yorkers, the need to adapt
quickly with ﬂuidity, ingenuity, and resiliency is well
ingrained as a result of the events of the past 2 decades.
This pandemic is unique and has forced all of us to
abandon our learned responses and standards of care to
better protect our patients and ourselves. We need to
defend ourselves from the moral injury that this contagion causes with a strategy that focuses on communication, collaboration, innovation, and humility. Early
planning and implementation of these strategies can help
minimize the collateral damage that may result and in
fact may help to establish new norms going forward.
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